Compounded Semaglutide vs Branded Wegovy: The Gap Has Nearly Closed

The standard version of this comparison is that compounded semaglutide costs a couple of hundred dollars and the branded pen costs well over a thousand. That was true. It has not been true for a while, and the reason is that Novo Nordisk started selling directly and cut its own cash price to compete.

Here is what the two sides actually charge in August 2026.

What the branded product costs when you buy it from the manufacturer

Novo's own pharmacy publishes a price table. Wegovy® pens are $349 a month at 0.25, 0.5, 1, 1.7 and 2.4 mg, with the 7.2 mg high-dose pen at $399. New patients get $199 a month for two fills, an offer that runs through 31 December 2026.¹

The Wegovy tablet is cheaper still: $149 a month at 1.5 mg, $199 at 4 mg, and $299 at 9 mg and 25 mg. A tablet month is one bottle of 30 tablets.¹

No membership. No care fee. One line on the bill.

What compounded semaglutide costs, seller by seller

Three published cash prices, each read off the seller's own page on 7 August 2026:

Strut Health — compounded oral semaglutide, $99 for a 30-day supply, with the page stating the price includes physician consultations and free shipping.² Its compounded injectable semaglutide with vitamin B6 is $149 a month.³

Found — $289 a month on the month-to-month plan, or $169 a month if you pay twelve months up front, which is $2,028 on day one.⁴ The compounded medication is included at any dose.

Zealthy — "Semaglutide Bundle: $217 for your first month, then $297 per month", all-in, in the seller's own words.⁵

Twelve months, side by side

Wegovy's tablet ladder, per its FDA label, starts at 1.5 mg for 30 days and titrates every 30 days to a maintenance dose of 25 mg once daily.⁶ Priced at Novo's published tiers, that first year is:

$149 + $199 + $299 + (9 × $299) = $3,338

The Wegovy pen, over 13 four-weekly fills: (2 × $199) + (11 × $349) = $4,237.

Found, month-to-month, twelve billing cycles: 12 × $289 = $3,468.

Zealthy: $217 + (11 × $297) = $3,484.

Strut, oral: 12 × $99 = $1,188. Strut, injectable: 12 × $149 = $1,788.

Read that column again. The FDA-approved tablet, bought direct from the company that makes it, costs less over a year than the compounded subscription at two of the three sellers we priced. Not less than all of them — Strut is genuinely and substantially cheaper — but the blanket claim that compounded is the budget option no longer survives contact with the price tables.

What is actually driving the difference

It is not the molecule. It is whether there is a membership underneath the medication.

Strut charges one number and says so on the page. Found and Zealthy bundle care into a subscription and price the bundle. Novo charges for the drug and nothing else, because the prescribing happens somewhere else entirely.

That is the variable worth checking first on any quote you are given: how many charges make up the number, and which of them recur. Our Found review, Strut Health review and Zealthy review take each bill apart line by line, and the current spread across the category sits on the compounded semaglutide board.

Compounded is not generic, and the FDA says so in those words

This is the part that pricing coverage routinely skips. Asked directly whether compounded and generic drugs are the same thing, the agency's answer is one word: "No. A generic drug is approved by FDA under 505(j) of the FD&C Act and meets all of the requirements of that section (including establishing therapeutic equivalence to a brand name drug, among others), while a compounded drug is not approved by FDA."⁷

So the $99 and the $349 are not two prices for the same regulatory object. One has an approval file behind it; the other does not. Whatever you conclude about value, the comparison is not brand-versus-generic and should not be reasoned about as though it were.

The FDA has published a price-based warning sign

In its standing guidance on unapproved GLP-1s, updated 15 June 2026, the agency lists warning signs that a telehealth company may be selling something you should not take. One of them is purely a pricing signal: a company that "offers medicine at deep discounts or prices that seem too good to be true".⁸

The same page notes that FDA has warned telehealth companies, active-ingredient distributors and outsourcing facilities over unapproved GLP-1 marketing, and records complaints of compounded GLP-1s arriving warm or without adequate refrigeration.⁸ Several sellers in this category carry warning letters of their own — Strut's is documented at /fda-letters/strut and Zealthy's at /fda-letters/zealthy. A letter is a disclosure, not a disqualification, but it belongs next to the price.

What we could not price

We could not verify Mochi Health's compounded semaglutide medication price from its own rendered page: the figures visible on joinmochi.com on 7 August 2026 were the $39 introductory and $79 ongoing membership charges, and the medication price did not render in the fetched HTML. It is therefore absent from the table above rather than estimated.

We could not price any of these against insurance, because no first-party source publishes plan-level cost sharing per drug.

And we could not establish a durable price for anything compounded. Every figure above is a subscription rate a seller may change, and several of these sellers' own terms say so explicitly.

Wegovy® is a registered trademark of Novo Nordisk A/S. Doseworth has no commercial relationship with Novo Nordisk.